Comments on IMVQuick blurb from Thom Calandra ...he's been a buying and recommending IMV for over 3 years..
IMV: Friday and next week look to be more gains for the outpacing shares of this Halifax lab.
“Abstracts,” or summaries, are just published for the annual ASCO cancer gathering in Chicago (early June). IMV’s abstract summarizes developments at the Halifax lab’s headline ovarian cancer clinical trials (with Incyte’s epacadostat drug).
https://abstracts.asco.org/214/AbstView_214_228043.html
For investors who “care” about the science, the online material from ASCO’s scores of abstracts are a pathway through the hype, paid promotions and sometimes, bogus analyst reports proliferating about success rates for dozens of pub-cos’ several cancer and infectious disease initiatives.
https://abstracts.asco.org/214/CatView_214_B.html
The IMV team (Olga Hrytsenko, Marianne Stanford and others) notes in its summary: “DPX-Survivac induces systemic survivin-specific T cell responses. T cells were demonstrated to migrate into tumors and correlated with objective clinical responses to combination therapy.”
I added yet again Wednesday to our stockpile of IMMVD shares (about $700,000 USD worth now and owned for three years in June). IMV shares in Toronto and in USA rose 7 percent to a new high today.
IMV shares will begin trading as a full-fledged NASDAQ stock in USA in early to mid-June (my estimate). Let’s hope we won’t see paid promotion masquerading as editorial for IMV, formerly Immunovaccine. The immuno-therapy company does not need to “raise” cash right now and almost surely will benefit from scientific journals and international media coverage that track its clinical progress across cancer, infectious disease and rabies. (www.imvaccine.com)
Frederic Ors, CEO of IMV Those suffering the rapid gutting and shortened life from ovarian cancer tumors, and regarding other IMV trials — lymphoma, RSV respiratory viruses, HPV virus and certain infectious diseases — will gain from any interaction with the immuno-therapies that IMV is developing.
Dana-Farber Cancer Institute just outside Boston is partnering with IMV for fresh applications that use IMV’s DepoVax-Survivac methodology. (Leidos, a healthcare consulting company with USA government ties, spun off from Lockheed-Martin, is working with IMV in the area of infectious diseases.)
For the art of the possible, or what is possible, in the ASCO (American Society of Clinical Oncology) data-preview arena each year regarding cancer treatments, please take a look today at a $4 billion company, LOXO Oncology, and its breast-cancer abstract for the conference. LOXO is the ticker in USA.
IMV shares (IMMVD in USA and IMV in Canada) appear to be on track to set fresh highs into the close of May and perhaps ahead of a NASDAQ listing. We’ll see.
A look at the stock chart for the OTC (USA) shares here appears to indicate that anyone who bought IMV’s stock in the past five years (actually for nearly all of its history as a pub-co and not just five years) is making money in their immunology therapy investment.
I am told by chart watchers and market “gaugers” that such a point in an investment’s strength carries with it a 75 percent chance of further points of gain within two weeks of occurrence.